STAAR Surgical Promotes Warren Foust to CEO Amid Record Growth
Event summary
- Warren Foust promoted to President and CEO of STAAR Surgical effective August 4, 2026.
- Deborah Andrews transitions to Executive Vice President and retains CFO role.
- STAAR reports strongest first half in company history with robust growth and profitability.
- China market shows sequential growth without inventory accumulation.
- EVO+ launch and improving product mix drive favorable ASP tailwinds.
The big picture
STAAR Surgical's promotion of Warren Foust to CEO comes at a pivotal moment, with the company reporting record growth and expanding its market share in refractive surgery. The shift from corneal tissue ablation to preservation aligns with broader industry trends, particularly as myopia rates are projected to rise globally. With over 4 million lenses sold in 85 countries, STAAR's strategic focus on revenue growth, profit expansion, and innovation acceleration positions it to capitalize on a significant market opportunity.
What we're watching
- Execution Risk
- Whether STAAR can sustain its growth momentum under new leadership.
- Market Dynamics
- The pace at which the global shift from corneal tissue ablation to preservation accelerates.
- Innovation Agenda
- How STAAR's transformation into a multi-product company will impact its market position.